Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €0.59 EUR
Change Today 0.00 / 0.00%
Volume 1.1M
ALEHT On Other Exchanges
Symbol
Exchange
EN Paris
OTC US
As of 11:35 AM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

diaxonhit (ALEHT) Snapshot

Open
€0.59
Previous Close
€0.59
Day High
€0.61
Day Low
€0.58
52 Week High
06/11/14 - €0.85
52 Week Low
10/15/14 - €0.47
Market Cap
41.6M
Average Volume 10 Days
909.6K
EPS TTM
€-0.09
Shares Outstanding
70.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DIAXONHIT (ALEHT)

Related News

No related news articles were found.

diaxonhit (ALEHT) Related Businessweek News

No Related Businessweek News Found

diaxonhit (ALEHT) Details

Diaxonhit discovers and commercializes specialty diagnostic products in the transplantation, infectious diseases, and cancer diagnosis specialty areas. Its commercialized product includes Tétanos Quick Stick, a proprietary test, which is used in emergency clinics for the evaluation of the protective status of a patient against tetanus. The company's in-house development products comprise the BJI InoPlex kit, a test that allows the detection of infections linked to articular prosthesis; and EHT Dx15, a test for the diagnosis of thyroid cancer, as well as licensed product includes AlloMap, a gene-expression profiling based blood test for regular and non-invasive surveillance of heart transplant recipients for acute cellular rejection. It is also involved in the development of companion diagnostics for resistant and breast cancers; and tests to monitor the direct effect of drug activity. Diaxonhit was founded in 1997 and is headquartered in Paris, France.

85 Employees
Last Reported Date: 04/30/15
Founded in 1997

diaxonhit (ALEHT) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

diaxonhit (ALEHT) Key Developments

Diaxonhit Grants Felicitex Therapeutics, Inc. Global Exclusive License

Diaxonhit announced that it granted an exclusive worldwide license to Felicitex Therapeutics Inc. Building upon discoveries made with its SpliceArray proprietary technology, Diaxonhit developed a program targeting the DYRK enzyme, which is involved in several pathogenic pathways related to cell proliferation. Diaxonhit believes this program has a strong potential and found, with Felicitex, a partner who shares the same interest in this innovative approach toward treating cancer. With this agreement, Felicitex acquires the rights for oncology to a lead series of novel small molecule anti-cancer compounds, which are highly active and selective against DYRK as validated by Felicitex in a pancreatic cancer model. The agreement is the culmination of a thorough due diligence process by both sides, as part of which Felicitex evaluated several members of the lead series in vitro and successfully demonstrated proof-of-concept efficacy in vivo in a pancreatic cancer mouse xenograft model.

Diaxonhit Announces Audited Consolidated Earnings Results for the Year Ended December 31, 2014

Diaxonhit announced audited consolidated earnings results for the year ended December 31, 2014. For the year, total revenues were EUR 31.7 million compared to EUR 31.2 million a year ago. Operating loss was EUR 5.4 million compared to EUR 6.8 million a year ago. Net loss was EUR 5.5 million compared to EUR 6.0 million a year ago. Diluted net result per share was EUR 0.09 per share compared to EUR 0.11 per share a year ago. Net cash used in operations was EUR 3,385,000 compared to EUR 4,901,000 a year ago. Purchase of tangibles and intangibles was EUR 658,000 compared to EUR 574,000 a year ago.

Diaxonhit Presents at CF&B European Small Cap Event, Apr-27-2015

Diaxonhit Presents at CF&B European Small Cap Event, Apr-27-2015 . Venue: Paris, France.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALEHT:FP €0.59 EUR 0.00

ALEHT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
NEL ASA 1.40 NOK +0.05
View Industry Companies
 

Industry Analysis

ALEHT

Industry Average

Valuation ALEHT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.1x
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIAXONHIT, please visit www.exonhit.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.